{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:24:41Z","timestamp":1780428281301,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.radonc.2012.07.003","type":"journal-article","created":{"date-parts":[[2012,7,30]],"date-time":"2012-07-30T21:18:19Z","timestamp":1343683099000},"page":"181-186","source":"Crossref","is-referenced-by-count":32,"title":["Long term results of a prospective dose escalation phase-II trial: Interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer"],"prefix":"10.1016","volume":"104","author":[{"given":"Sebastian","family":"Lettmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kreppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annedore","family":"Strnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratislav","family":"Strnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2012.07.003_b0005","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1887::AID-CNCR11>3.0.CO;2-P","article-title":"Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy","volume":"82","author":"D\u2019Amico","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2012.07.003_b0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0360-3016(97)89478-3","article-title":"Pulsed low dose rate brachytherapy in a rat model: dependence of late rectal injury on radiation pulse size","volume":"38","author":"Armour","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0360-3016(97)00097-7","article-title":"Pulsed-dose-rate brachytherapy: design of convenient (daytime-only) schedules","volume":"39","author":"Brenner","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0360-3016(96)00565-2","article-title":"Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues","volume":"37","author":"Fowler","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF03038351","article-title":"In vitro studies of PDR brachytherapy","volume":"174","author":"Fritz","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2012.07.003_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-8140(97)00166-7","article-title":"Pulsed dose-rate brachytherapy","volume":"45","author":"Hall","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0924-4212(96)81504-0","article-title":"Is \u201cpulse dose rate\u201d curietherapy comparable to low dose rate brachytherapy?","volume":"82","author":"Lartigau","year":"1995","journal-title":"Bull Cancer Radiother"},{"key":"10.1016\/j.radonc.2012.07.003_b0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0360-3016(94)90192-9","article-title":"Comparison of continuous and pulsed low dose rate brachytherapy: biological equivalence in vivo","volume":"28","author":"Mason","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0167-8140(95)01695-3","article-title":"Constraints in the use of repair half times and mathematical modelling for the clinical application of HDR and PDR treatment schedules as an alternative for LDR brachytherapy","volume":"38","author":"Pop","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0360-3016(96)00564-0","article-title":"Pulsed low dose rate brachytherapy for pelvic malignancies","volume":"37","author":"Swift","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0360-3016(98)00367-8","article-title":"Pulsed low dose rate brachytherapy for uterine cervix carcinoma","volume":"43","author":"Rogers","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0360-3016(97)00046-1","article-title":"Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate","volume":"38","author":"Levendag","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00066-009-1943-6","article-title":"Accelerated partial-breast irradiation with interstitial implants. Analysis of factors affecting cosmetic outcome","volume":"185","author":"Ott","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2012.07.003_b0070","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00066-005-1424-5","article-title":"Role of interstitial PDR brachytherapy in the treatment of oral and oropharyngeal cancer. A single-institute experience of 236 patients","volume":"181","author":"Strnad","year":"2005","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2012.07.003_b0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1538-4721(03)00132-6","article-title":"The role of pulsed-dose-rate brachytherapy in previously irradiated head-and-neck cancer","volume":"2","author":"Strnad","year":"2003","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2012.07.003_b0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0360-3016(95)02054-3","article-title":"Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments","volume":"34","author":"Visser","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0085","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0360-3016(00)01443-7","article-title":"Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy","volume":"49","author":"Horwitz","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2012.07.003_b0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0360-3016(96)00513-5","article-title":"Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer","volume":"37","author":"Laverdiere","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2005.06.005","article-title":"Bicalutamide (\u2018Casodex\u2019) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme","volume":"76","author":"Tyrrell","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0115","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2012.07.003_b0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0125","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0130","first-page":"346","article-title":"Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment","volume":"3","author":"Stromberg","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.radonc.2012.07.003_b0135","series-title":"Time\u2013dose relationship: the linear quadratic approach","author":"Joiner","year":"2002"},{"key":"10.1016\/j.radonc.2012.07.003_b0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The alpha\/beta ratio for prostate cancer: what is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijrobp.2004.07.723","article-title":"Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy","volume":"61","author":"Cheung","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2004.12.019","article-title":"Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy","volume":"75","author":"Valdagni","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/srao.2002.28667","article-title":"Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes","volume":"12","author":"Blasko","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0165","first-page":"25","article-title":"Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives","volume":"174","author":"Seegenschmiedt","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2012.07.003_b0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijrobp.2006.04.002","article-title":"Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer","volume":"66","author":"Izard","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0210","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ijrobp.2009.12.044","article-title":"Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer","volume":"79","author":"Pieters","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijrobp.2006.07.1382","article-title":"15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience","volume":"67","author":"Sylvester","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0196-0709(95)90077-2","article-title":"Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value","volume":"16","author":"Klapan","year":"1995","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.radonc.2012.07.003_b0190","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy\u2019s 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0195","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijrobp.2006.04.045","article-title":"High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study","volume":"66","author":"Vargas","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.07.003_b0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.radonc.2008.02.023","article-title":"Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy","volume":"88","author":"Pieters","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.07.003_b0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012003192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012003192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T20:25:55Z","timestamp":1542831955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814012003192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0167814012003192"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2012.07.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}